Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1455-1463

  Liersch, Ruediger ^a,b,c   Shin, Jay W ^b,c   Bayer, Michael ^a   Schwöppe, Christian ^a   Schliemann, Christoph ^a   Berdel, Wolfgang E ^a   Mesters, Rolf ^a   Detmar, Michael ^b,c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ETH ZURICH   (Switzerland)

Author keywords

Cancer; Lymphangiogenesis; Lymphatic endothelial cells; Metastasis; Osteopontin

Indexed keywords

ALPHA INTEGRIN; ALPHA9 INTEGRIN; ANGIOGENIC FACTOR; OSTEOPONTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPH FLOW; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MELANOMA; MELANOMA CELL; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE; WESTERN BLOTTING;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA CHAINS; LYMPH NODES; LYMPHANGIOGENESIS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OSTEOPONTIN; SIGNAL TRANSDUCTION;

EID: 84866495053     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1548     Document Type: Article

References (41)

1. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al: Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol: 1232-1242, 2005.
2. He Y, Rajantie I, Pajusola K, et al: Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65: 4739-4746, 2005.
3. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF and Detmar M: VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201: 1089-1099, 2005.
4. Skobe M, Hawighorst T, Jackson DG, et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192-198, 2001.
5. Stacker SA, Caesar C, Baldwin ME, et al: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186-191, 2001.
6. McGuire WL: Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 10: 5-9, 1987.
7. Foster RS Jr: The biologic and clinical significance of lymphatic metastases in breast cancer. Surg Oncol Clin N Am 5: 79-104, 1996.
8. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634, 2001.
9. Mandriota SJ, Jussila L, Jeltsch M, et al: Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672-682, 2001.
10. Dadras SS, Paul T, Bertoncini J, et al: Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 162: 1951-1960, 2003.
11. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K and Detmar M: VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109: 1010-1017, 2007.
12. Hay JB and Hobbs BB: The flow of blood to lymph nodes and its relation to lymphocyte traffic and the immune response. J Exp Med 145: 31-44, 1977.
13. Cahill RN, Frost H and Trnka Z: The effects of antigen on the migration of recirculating lymphocytes through single lymph nodes. J Exp Med 143: 870-888, 1976.
14. Hall JG and Morris B: The immediate effect of antigens on the cell output of a lymph node. Br J Exp Pathol 46: 450-454, 1965.
15. He Y, Kozaki K, Karpanen T, et al: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94: 819-825, 2002.
16. Detmar M and Hirakawa S: The formation of lymphatic vessels and its importance in the setting of malignancy. J Exp Med 196: 713-718, 2002.
17. Gehlsen KR and Hendrix MJ: In vitro assay demonstrates similar invasion profiles for B16F1 and B16F10 murine melanoma cells. Cancer Lett 30: 207-212, 1986.
18. Kajiya K, Hirakawa S, Ma B, Drinnenberg I and Detmar M: Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24: 2885-2895, 2005.
19. Ishimatsu-Tsuji Y, Moro O and Kishimoto J: Expression profiling and cellular localization of genes associated with the hair cycle induced by wax depilation. J Invest Dermatol 125: 410-420, 2005.
20. Hirakawa S, Hong YK, Harvey N, et al: Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 162: 575-586, 2003.
21. Reinmuth N, Liersch R, Raedel M, et al: Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer. Int J Cancer 124: 1535-1544, 2009.
22. Gentleman RC, Carey VJ, Bates DM, et al: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80, 2004.
23. Huber W, von Heydebreck A, Sultmann H, Poustka A and Vingron M: Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 (Suppl 1): S96-S104, 2002.
24. Tai YC and Speed TP: A multivariate empirical Bayes statistics for replicated microarray time course data. Ann Stat 34: 2387-2412, 2006.
25. Thomas PD, Kejariwal A, Guo N, et al: Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 34: W645-W650, 2006.
26. Fisher B and Fisher ER: The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 122: 791-798, 1966.
27. Harrell MI, Iritani BM and Ruddell A: Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 170: 774-786, 2007.
28. Ruddell A, Mezquita P, Brandvold KA, Farr A and Iritani BM: B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am J Pathol 163: 2233-2245, 2003.
29. Brown LF, Papadopoulos-Sergiou A, Berse B, et al: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145: 610-623, 1994.
30. Casson AG, Wilson SM, McCart JA, et al: ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 72: 739-745, 1997.
31. Denhardt DT, Giachelli CM and Rittling SR: Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41: 723-749, 2001.
32. Rittling SR and Novick KE: Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ 8: 1061-1069, 1997.
33. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87, 2006.
34. Zhou Y, Dai DL, Martinka M, et al: Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 124: 1044-1052, 2005.
35. Hayashi C, Rittling S, Hayata T, et al: Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. J Cell Biochem 101: 979-986, 2007.
36. Rangel J, Nosrati M, Torabian S, et al: Osteopontin as a molecular prognostic marker for melanoma. Cancer 112: 144-150, 2008.
37. Haqq C, Nosrati M, Sudilovsky D, et al: The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102: 6092-6097, 2005.
38. Gardner HA, Berse B and Senger DR: Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9: 2321-2326, 1994.
39. Chakraborty G, Jain S and Kundu GC: Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68: 152-161, 2008.
40. Avraamides CJ, Garmy-Susini B and Varner JA: Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604-617, 2008.
41. Smith LL and Giachelli CM: Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Exp Cell Res 242: 351-360, 1998.